Taysha’s Gene Therapy Steals Spotlight With Early Phase I/II Data In Rett Syndrome
Stock Up By 285%
The US biotech’s TSHA-102 has shown surprisingly early signs of functional improvement in a single patient treated in its Phase I/II Rett syndrome trial, promoting a major stock surge supported by the news of a $150 private placement and regulatory updates.
